- Home
- RNAZ vs EVGN Comparison
RNAZ vs EVGN Comparison
Compare RNAZ & EVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- EVGN
- Stock Information
- Founded
- RNAZ 2016
- EVGN 1999
- Country
- RNAZ United States
- EVGN Israel
- Employees
- RNAZ N/A
- EVGN N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- EVGN Agricultural Chemicals
- Sector
- RNAZ Health Care
- EVGN Industrials
- Exchange
- RNAZ Nasdaq
- EVGN Nasdaq
- Market Cap
- RNAZ 8.3M
- EVGN 9.7M
- IPO Year
- RNAZ 2021
- EVGN N/A
- Fundamental
- Price
- RNAZ $0.32
- EVGN $1.71
- Analyst Decision
- RNAZ Strong Buy
- EVGN Strong Buy
- Analyst Count
- RNAZ 1
- EVGN 1
- Target Price
- RNAZ $3.00
- EVGN $12.00
- AVG Volume (30 Days)
- RNAZ 606.0K
- EVGN 791.7K
- Earning Date
- RNAZ 11-26-2024
- EVGN 11-21-2024
- Dividend Yield
- RNAZ N/A
- EVGN N/A
- EPS Growth
- RNAZ N/A
- EVGN N/A
- EPS
- RNAZ N/A
- EVGN N/A
- Revenue
- RNAZ N/A
- EVGN $9,449,000.00
- Revenue This Year
- RNAZ N/A
- EVGN $173.12
- Revenue Next Year
- RNAZ $100.00
- EVGN $33.10
- P/E Ratio
- RNAZ N/A
- EVGN N/A
- Revenue Growth
- RNAZ N/A
- EVGN 290.29
- 52 Week Low
- RNAZ $0.22
- EVGN $1.70
- 52 Week High
- RNAZ $18.68
- EVGN $10.40
- Technical
- Relative Strength Index (RSI)
- RNAZ 33.05
- EVGN 31.72
- Support Level
- RNAZ $0.31
- EVGN $1.70
- Resistance Level
- RNAZ $0.49
- EVGN $2.10
- Average True Range (ATR)
- RNAZ 0.05
- EVGN 0.21
- MACD
- RNAZ -0.02
- EVGN -0.01
- Stochastic Oscillator
- RNAZ 12.67
- EVGN 4.27
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
About EVGN Evogene Ltd
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment followed by Industry.